text
"['\n3. 원재료 및 생산설비\n가. 주요 원재료\n(단위: 천원, %)\n사업부문\n매입유형\n품목\n매입액\n비율\n비 \xa0고\n의약품\n원재료\n데스벤라팍신\n2,750,788\n10.63\n수입\n콜린알포세레이트\n516,000\n1.99\n국내\n날트렉손염산염\n1,318,135\n5.09\n수입\n도네페질염산염\n134,750\n0.52\n국내\n아토목세틴염산염\n920,000\n3.55\n국내\n기타원재료\n7,337,792\n28.35\n국내\n12,910,760\n49.87\n수입\n합 \xa0 계\n25,888,225\n100.00\n-\n나. 주요 원재료 등 가격변동 추이\n(단위: 천원)\n품 \xa0목\n단위\n제43기 반기\n제42기\n제41기\n콜린알포세레이트\nkg\n430,000\n430,000\n430,000\n날트렉손염산염\nkg\n8,787,568\n8,451,439\n8,742,876\n도네페질염산염\nkg\n2,450,000\n2,450,000\n2,350,000\n데스벤라팍신\nkg\n1,892,647\n2,159,977\n2,030,213\n아토목세틴염산염\nkg\n2,300,000\n2,500,000\n2,430,090\n다. 생산능력 및 생산능력의 산출 근거(1) 생산능력\r\n(단위: 백만원)\n사업부문\n품 \xa0목\n사업소\n제43기 반기\n\xa0제42기\n제41기\n의약품부문\n정신신경용제\n안성공장및향남공장\n43,200\n80,500\n67,000\n순환계용약\n3,500\n6,000\n4,500\n해열 소염 진통제\n1,100\n2,000\n2,500\n소화성궤양용제\n800\n2,500\n1500\n골다공증 치료제\n100\n1,000\n250\n기 \xa0 타\n2,100\n4,500\n4,000\n합 \xa0 계\n50,800\n96,500\n79,750\n(2) 생산능력의 산출근거\n(가) 산출방법 등\n① 산출기준\n생산능력은 각 제품별 라인별 연간 가능 최대 가동시간을 기준으로 하여 산출되었으며, 생산실적은 실제로 생산된 완제품의 제조원가 명세서를 기준으로 산출하였습니다.\n② 평균 가동시간\n당반기말 182일 중 휴무일을 제외하고 하루 평균 8시간 가동\n(나) 생산실적\nⓛ 생산실적\n(단위: 백만원)\n사업부문\n품 \xa0목\n사업소\n제43기 반기\n제42기\n제41기\n의약품부문\n정신신경용제\n안성공장및향남공장\n37,596\n72,344\n60,745\n순환계용약\n3,056\n5,263\n3,828\n해열 소염 진통제\n970\n1,710\n2,311\n소화성궤양용제\n680\n1,975\n1,033\n골다공증 치료제\n96\n69\n204\n기 \xa0 타\n1,868\n4,059\n3,645\n합 \xa0 계\n44,266\n85,420\n71,766\n② 가동률\n(단위: 시간, %)\n사업소(사업부문)\n당반기가동가능시간\n당반기실제가동시간\n평균가동률\n의약품 부문\n952\n830\n87.18\n합 \xa0 계\n952\n830\n87.18\n라. 생산설비의 현황 등(1) 생산설비의 현황\n[자산항목: 토지]\n(단위: 천원)\n사업소\n소유형태\n소재지\n기초장부가액\n증감\n상각액\n장부가액\n비고\n증가\n감소\n본사\n자가\n서울\n6,251,295\n-\n-\n-\n6,251,295\n안성공장\n자가\n안성\n7,304,479\n-\n-\n-\n7,304,479\n향남공장\n자가\n향남\n28,423,048\n-\n-\n-\n28,423,048\n연구소\n자가\n기흥\n7,593,379\n-\n-\n-\n7,593,379\n합 \xa0 계\n49,572,201\n-\n-\n-\n49,572,201\n[자산항목: 건물]\n(단위: 천원)\n사업소\n소유형태\n소재지\n기초장부가액\n증감\n상각액\n장부가액\n비고\n증가\n감소\n본사\n자가\n서울\n7,929,882\n-\n-\n166,361\n7,763,521\n안성공장\n자가\n안성\n4,271,969\n-\n-\n201,649\n4,070,320\n향남공장\n자가\n향남\n7,720,105\n7,545,749\n4,878\n217,809\n15,043,167\n연구소\n자가\n기흥\n8,025,459\n-\n-\n138,370\n7,887,089\n합 \xa0 계\n27,947,415\n7,545,749\n4,878\n724,189\n34,764,097\n[자산항목: 건물부속설비]\n(단위: 천원)\n사업소\n소유형태\n소재지\n기초장부가액\n증감\n상각액\n장부가액\n비고\n증가\n감소\n안성공장\n자가\n안성\n319,692\n-\n-\n8,207\n311,485\n향남공장\n자가\n향남\n280,600\n-\n-\n4,880\n275,720\n합 \xa0 계\n600,292\n-\n-\n13,087\n587,205\n[자산항목: 구축물]\n(단위: 천원)\n사업소\n소유형태\n소재지\n기초장부가액\n증감\n상각액\n장부가액\n비고\n증가\n감소\n안성공장\n자가\n안성\n8,512\n-\n8,368\n140\n4\n합 \xa0 계\n8,512\n-\n8,368\n140\n4\n[자산항목: 차량운반구]\n(단위: 천원)\n사업소\n소유형태\n소재지\n기초장부가액\n증감\n상각액\n장부가액\n비고\n증가\n감소\n안성공장\n자가\n안성\n79,626\n-\n-\n5,534\n74,092\n향남공장\n자가\n향남\n32,323\n-\n-\n1,847\n30,476\n합 \xa0 계\n111,949\n-\n-\n7,381\n104,568\n[자산항목: 공기구비품]\n(단위: 천원)\n사업소\n소유형태\n소재지\n기초장부가액\n증감\n상각액\n장부가액\n비고\n증가\n감소\n본사\n자가\n서울\n393,780\n76,000\n-\n65,358\n404,422\n안성공장\n자가\n안성\n4,875,708\n598,414\n3,392\n383,120\n5,087,610\n향남공장\n자가\n향남\n9,721,751\n1,194,598\n-\n566,746\n10,349,603\n연구소\n자가\n기흥\n5,075,575\n681,634\n-\n411,314\n5,345,895\n합 \xa0 계\n20,066,814\n2,550,646\n3,392\n1,426,538\n21,187,530\n[자산항목: 기계장치]\n(단위: 천원)\n사업소\n소유형태\n소재지\n기초장부가액\n증감\n상각액\n장부가액\n비고\n증가\n감소\n안성공장\n자가\n안성\n3,733,980\n269,000\n-\n373,976\n3,629,004\n향남공장\n자가\n향남\n9,547,340\n708,200\n3,089\n551,102\n9,701,349\n합 \xa0 계\n13,281,320\n977,200\n3,089\n925,078\n13,330,353\n[자산항목: 건설중인자산]\n(단위: 천원)\n사업소\n소유형태\n소재지\n기초장부가액\n증감\n상각액\n장부가액\n비고\n증가\n감소\n본사\n자가\n서울\n38,000\n38,000\n76,000\n-\n-\n안성공장\n자가\n안성\n13,497,931\n15,905,396\n691,450\n-\n28,711,877\n향남공장\n자가\n향남\n5,340,357\n4,278,592\n8,865,949\n-\n753,000\n연구소\n자가\n기흥\n-\n134,000\n134,000\n-\n-\n합 \xa0 계\n18,876,288\n20,355,988\n9,767,399\n-\n29,464,877\n2) 설비의 신설ㆍ매입 계획 등① 진행중인 투자\n(단위: 천원)\n사업부문\n구 분\n투자기간\n투자대상 자산\n투자효과\n총투자액\n기투자액\n향후투자액\n비 고\n의약품제조업\n매입\n2024. 01. 01 ~ 06.30\n건물\n효율성 증대\n-\n7,545,749\n-\n-\n매입\n2024. 01. 01 ~ 06.30\n공기구비품\n효율성 증대\n-\n2,550,646\n-\n-\n매입\n2024. 01. 01 ~ 06.30\n기계장치\n효율성 증대\n-\n977,200\n-\n-\n매입\n2024. 01. 01 ~ 06.30\n건설중인자산\n효율성 증대\n-\n10,588,589\n-\n-\n합 계\n-\n21,662,184\n-\n-\n']"
